{"id":"W2755130106","doi":"10.1136/annrheumdis-2017-eular.2148","title":"AB0756 Primary efficacy and safety of adalimumab in nail psoriasis from the first 26 weeks of a phase-3, randomized, placebo-controlled trial with subanalysis in patients with and without psoriatic arthritis","year":2017,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Incyte; Valeant Pharmaceuticals International; AbbVie; Celgene; Amgen; Pfizer; Allergan; Eli Lilly and Company","keywords":"Medicine; Psoriatic arthritis; Concomitant; Psoriasis; Adalimumab; Placebo; Adverse effect; Internal medicine; Randomized controlled trial; Clinical endpoint; Psoriasis Area and Severity Index; Surgery; Dermatology; Gastroenterology; Rheumatoid arthritis; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002393094,0.002005074,0.006063347,0.0006520002,0.0007351586,0.001718134,0.0009200642,0.001624343,0.005117161],"category_scores_gemma":[0.001703528,0.0009307292,0.00406233,0.0005438947,0.001256449,0.001330589,0.0004946329,0.00326821,0.001270906],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007695448,"about_ca_system_score_gemma":0.0009932687,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007233815,"about_ca_topic_score_gemma":0.001527984,"domain_scores_codex":[0.9988033,0.0005636291,0.00009984393,0.0002350185,0.00009048096,0.0002077371],"domain_scores_gemma":[0.9988268,0.0003279596,0.0002238293,0.0001221428,0.0001087603,0.0003905566],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9823452,0.002901442,0.0008162545,0.0004501985,0.001715079,0.00003285984,0.00002942297,0.0002188041,0.002489743,0.00003879638,0.0002795856,0.008682572],"study_design_scores_gemma":[0.915121,0.0761973,0.005094248,0.00004567039,0.001966682,0.00005576864,0.00003319966,0.0003175852,0.0005561684,0.0001220294,0.0004633369,0.00002710835],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.986114,0.0086645,0.0005173387,0.0003268624,0.0004897388,0.001516828,0.0007001212,0.0001099212,0.001560791],"genre_scores_gemma":[0.991155,0.002812222,0.0007602706,0.0007283922,0.0004228058,0.001366753,0.0008737444,0.00002983085,0.001850998],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006063347,"threshold_uncertainty_score":0.01711857,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01247046845713565,"score_gpt":0.2457587891840226,"score_spread":0.2332883207268869,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}